Currently Viewing:
Newsroom
Currently Reading
Patients With Psoriasis Have Higher Risk of Liver Disease Compared With Patients With RA
November 14, 2017 – Laura Joszt
From Bacteria to Eczema: Johns Hopkins Team Studies How Inflammation Happens
November 09, 2017 – Mary Caffrey
Mutation May Be Associated With Resistance to NSCLC Immunotherapy
November 08, 2017 – Smita Jaggernauth, PharmD
Having a Dog May Protect Children From Eczema
November 08, 2017 – Mary Caffrey
Roche Gets Drug Approvals for First Treatment for a Rare Blood Disorder and NSCLC
November 07, 2017 – AJMC Staff
Study Investigates the Effects of GSK-3 Inhibition to Improve Understanding of Leukemia
November 06, 2017 – Alison Rodriguez
Study Recommends Surveillance Rather Than Surgery for Non-Cancerous Breast Lesions
November 05, 2017 – Alison Rodriguez
Treg Cells Continue Suppressing Immunotherapy Even After They Are Eliminated
November 03, 2017 – Alison Rodriguez
5 Significant OCM Questions Addressed During the COA Payer Summit
November 03, 2017 – Surabhi Dangi-Garimella, PhD

Patients With Psoriasis Have Higher Risk of Liver Disease Compared With Patients With RA

Laura Joszt
Patients with psoriasis and with rheumatoid arthritis (RA) are often treated with similar drugs, but those with psoriasis are at a higher risk for serious liver disease, according to a new study in the Journal of Investigative Dermatology.
Patients with psoriasis and with rheumatoid arthritis are often treated with similar drugs, but those with psoriasis are at a higher risk for serious liver disease, according to a new study in the Journal of Investigative Dermatology.

Researchers from the Perelman School of Medicine at the University of Pennsylvania (UPenn) studied more than 197,000 patients with psoriasis, 12,000 patients with psoriatic arthritis, 54,000 patients with rheumatoid arthritis (RA), and 1.2 million matched controls. Outcomes of interest were any liver disease, non-alcoholic fatty liver disease, and cirrhosis.

Patients with psoriatic skin or joint disease had a higher risk for serious liver disease, and patients with psoriasis taking a systemic therapy drug had the highest risk. Patients with RA taking similar drugs had the lowest liver disease risk.

The study also found that as the body surface area affected by psoriasis increased, so did the prevalence of liver disease and cirrhosis. In general, previous research has found that severity of psoriasis is linked to an increased risk of death. A study from UPenn researchers published in the same journal in August found that patients with psoriasis on 10% or more of their body had nearly double the risk of death.

The study adjusts for risk factors commonly seen in liver disease, such as alcohol use and diabetes.

“These findings offer evidence for the long-held view that psoriasis patients may be more predisposed to liver disease than patients with rheumatoid arthritis,” first author Alexis Ogdie, MD, MSCE, an assistant professor of Medicine and Epidemiology at the University of Pennsylvania, said in a statement. “Understanding the role of inflammation in liver disease and how the liver can perpetuate inflammation in these conditions can help us advise patients, and their clinicians, on how to more effectively manage their health.” 

According to the authors, the findings suggest that systemic inflammation plays a significant role in liver disease development, but that medications used to treat these diseases can cause liver toxicity.

The authors suggest that future research look into whether control of inflammation reduces risk of liver disease.

“Based on these data, physicians should educate psoriasis patients on the increased risk for liver disease and be cautious about the use of hepatoxic medications in these patients, especially when additional risk factors such as diabetes, obesity, or heavy alcohol use are present,” said senior author Joel M. Gelfand, MD, MSCE, a professor of Dermatology and Epidemiology at UPenn.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up